Browse

Salvage Treatment for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Efficacy of Linezolid With or Without Carbapenem

DC Field Value Language
dc.contributor.authorJang, Hee-Chang-
dc.contributor.authorKim, Sung-Han-
dc.contributor.authorKim, Kye Hyoung-
dc.contributor.authorKim, Choong Jong-
dc.contributor.authorSong, Kyoung-Ho-
dc.contributor.authorPark, Wan Beom-
dc.contributor.authorPark, Sang-Won-
dc.contributor.authorKim, Eui-Chong-
dc.contributor.authorChoe, Kang Won-
dc.contributor.authorOh, Myoung-don-
dc.contributor.authorKim, Nam Joong-
dc.contributor.authorKim, Hong Bin-
dc.contributor.authorJeon, Jae Hyun-
dc.contributor.authorLee, Shinwon-
dc.date.accessioned2012-05-24T05:11:02Z-
dc.date.available2012-05-24T05:11:02Z-
dc.date.issued2009-08-01-
dc.identifier.citationCLINICAL INFECTIOUS DISEASES; Vol.49 3; 395-401ko_KR
dc.identifier.issn1058-4838-
dc.identifier.urihttps://hdl.handle.net/10371/76403-
dc.description.abstractBackground. Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high mortality rates, but no treatment strategy has yet been established. We performed this study to evaluate the efficacy of linezolid with or without carbapenem in salvage treatment for persistent MRSA bacteremia. Methods. All adult patients with persistent MRSA bacteremia for >= 7 days from January 2006 through March 2008 who were treated at Seoul National University Hospital were studied. The results of linezolid salvage therapy with or without carbapenem were compared with those of salvage therapy with vancomycin plus aminoglycosides or rifampicin. Results. Thirty-five patients with persistent MRSA bacteremia were studied. The early microbiological response (ie, negative results for follow-up blood culture within 72 hours) was significantly higher in the linezolid-based salvage therapy group than the comparison group (75% vs 17%; P = .006). Adding aminoglycosides or rifampicin to vancomycin was not successful in treating any of the patients, whereas linezolid-based therapy gave an 88% salvage success rate (P < .001). The S. aureus-related mortality rate was lower for patients treated with a linezolid salvage regimen than for patients continually treated with a vancomycin-based regimen (13% vs 53%; P = .030). Conclusions. Linezolid-based salvage therapy effectively eradicated S. aureus from the blood for patients with persistent MRSA bacteremia. The salvage success rate was higher for linezolid therapy than for vancomycin-based combination therapy.ko_KR
dc.language.isoenko_KR
dc.publisherUNIV CHICAGO PRESSko_KR
dc.titleSalvage Treatment for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Efficacy of Linezolid With or Without Carbapenemko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor장희창-
dc.contributor.AlternativeAuthor김성한-
dc.contributor.AlternativeAuthor김계형-
dc.contributor.AlternativeAuthor김충종-
dc.contributor.AlternativeAuthor이신원-
dc.contributor.AlternativeAuthor송경호-
dc.contributor.AlternativeAuthor전재현-
dc.contributor.AlternativeAuthor박완범-
dc.contributor.AlternativeAuthor김홍빈-
dc.contributor.AlternativeAuthor박상원-
dc.contributor.AlternativeAuthor김남중-
dc.contributor.AlternativeAuthor김의종-
dc.contributor.AlternativeAuthor오명돈-
dc.contributor.AlternativeAuthor최강원-
dc.identifier.doi10.1086/600295-
dc.citation.journaltitleCLINICAL INFECTIOUS DISEASES-
dc.description.citedreferenceJenkins TC, 2008, CLIN INFECT DIS, V46, P1000, DOI 10.1086/529190-
dc.description.citedreferenceFalagas ME, 2008, LANCET INFECT DIS, V8, P53, DOI 10.1016/S1473-3099(07)70312-2-
dc.description.citedreferenceHawkins C, 2007, ARCH INTERN MED, V167, P1861-
dc.description.citedreferenceKollef MH, 2007, CLIN INFECT DIS, V45, pS191, DOI 10.1086/519470-
dc.description.citedreferenceMicek ST, 2007, CLIN INFECT DIS, V45, pS184, DOI 10.1086/519471-
dc.description.citedreference*CLIN LAB STAND I, 2007, M100S17 CLIN LAB STA-
dc.description.citedreferenceHidayat LK, 2006, ARCH INTERN MED, V166, P2138-
dc.description.citedreferenceHowden BP, 2006, ANTIMICROB AGENTS CH, V50, P3039, DOI 10.1128/AAC.00422-06-
dc.description.citedreferenceHageman JC, 2006, CLIN INFECT DIS, V43, pE42-
dc.description.citedreferenceJacqueline C, 2006, ANTIMICROB AGENTS CH, V50, P2547, DOI 10.1128/AAC.01501-05-
dc.description.citedreferenceSakoulas G, 2006, CLIN INFECT DIS, V42, pS40-
dc.description.citedreferenceJones RN, 2006, CLIN INFECT DIS, V42, pS13-
dc.description.citedreferenceKhatib R, 2006, SCAND J INFECT DIS, V38, P7, DOI 10.1080/00365540500372846-
dc.description.citedreferenceWu VC, 2006, CLIN INFECT DIS, V42, P66-
dc.description.citedreferenceJacqueline C, 2005, ANTIMICROB AGENTS CH, V49, P45, DOI 10.1128/AAC.49.1.45-51.2005-
dc.description.citedreference*CDCP, 2005, CA MRSA CLIN FAQS CD-
dc.description.citedreferenceFowler VG, 2004, J INFECT DIS, V190, P1140-
dc.description.citedreferenceWisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946-
dc.description.citedreferenceKhosrovaneh A, 2004, CLIN INFECT DIS, V38, P1328-
dc.description.citedreferenceHowden BP, 2004, CLIN INFECT DIS, V38, P521-
dc.description.citedreferenceKIM SH, 2004, 42 ANN M INF DIS SOC, P142-
dc.description.citedreferenceFowler VG, 2003, ARCH INTERN MED, V163, P2066-
dc.description.citedreferenceKim SH, 2003, CLIN INFECT DIS, V37, P794-
dc.description.citedreferenceMoise PA, 2002, J ANTIMICROB CHEMOTH, V50, P1017, DOI 10.1093/jac/dkf215-
dc.description.citedreferenceLi JS, 2000, CLIN INFECT DIS, V30, P633-
dc.description.citedreferenceYou I, 2000, DIAGN MICR INFEC DIS, V36, P37-
dc.description.citedreferenceLowy FD, 1998, NEW ENGL J MED, V339, P520-
dc.description.citedreferenceHiramatsu K, 1997, LANCET, V350, P1670-
dc.description.citedreferenceLIBMAN H, 1984, ARCH INTERN MED, V144, P541-
dc.description.tc17-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Laboratory Medicine (검사의학전공)Journal Papers (저널논문_검사의학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse